Skip to main content

Table 2 Laboratory and clinical characteristics of patients with and without pathological levels of fecal elastase

From: Exocrine pancreatic function is preserved in systemic sclerosis

  ALT (U/L) AST (U/L) GGT (U/L) ALP (U/L) Pancreatic amylase (U/L) Calcium (mmol/l) Magnesium (mmol/l) Albumin (g/l) Prealbumin (g/l) Vitamin D3 (nmol/l) Disease duration (years) Age (years) ACA (n) ATA (n) ARA (n)
FE ≤ 200 μg/g (n = 6) 25 (16–41) 29 (22, 40) 55 (22, 156) 71 (71,881.2) 24 (22, 32) 2.4 (2.3, 2.5) 0.93 (0.77, 1.1) 40 (37, 42) 0.33 (0.19, 0.36) 48 (29, 65) 5 (1, 15) 70 (57, 76) 1 1 1
FE > 200 μg/g (n = 106) 19 (14, 24) 24 (21, 29) 25 (17, 0.46) 71 (52, 81) 25 (18, 0.38) 2.3 (2.3, 2.4) 0.82 (0.77, 0.86) 39 (36, 41) 0.25 (0.2, 0.3) 70 (45, 78) 7(3, 15) 60 (61, 69) 38 19 9
  1. Systemic sclerosis patients with pathological FE testing did not differ compared to other patients with regard to laboratory markers of liver function and malnutrition, disease duration, age, and antibody profile. p > 0.05 for all variables when comparing patients with FE ≤ 200 μg/g to patients with FE > 200 μg/g. Values are given as median (interquartile range)
  2. FE fecal elastase, ALT alanin aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase, ALP alkaline phosphatase, ACA anti-centromere antibodies, ATA anti-topoisomerase antibodies, ARA anti-RNA polymerase III antibodies